Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lip filler under the microscope: can RefillHA lips smooth mild defects for a year?

NCT ID NCT07831213

NEW Symptom relief Sponsor: Glyance Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are observing how well RefillHA Lips, a hyaluronic acid filler, remodels and corrects mild lip defects in adults. The study follows 87 men and women aged 18 and older for 12 months after injection. Investigators track aesthetic improvement using a standard scale and monitor safety. The goal is to see whether the filler keeps lips looking better over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a hyaluronic acid lip filler called RefillHA Lips
What this could lead to
If it works, this could give people with mild lip defects a filler option backed by a year of safety and improvement data.
What could go wrong
This is an observational study of an already-marketed filler, so it cannot prove cause and effect. Results may not apply to people with severe lip defects or those who recently had other fillers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 87 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects over the age of 18 who are seeking remodelling and/or correction of mild defects of the lips.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women of any race, 18 years of age or older. * Able to read, understand and sign informed consent. Exclusion Criteria: * Subjects with known contraindications to the treatment with RefillHA Lips, as per the device IFU. * Patients with multiple and/or severe allergies or history of anaphylaxis. * Pregnant or lactating women (contraindications as per IFU). * Having received prior dermal filler injections in the six months preceding the study. * Previously treated with semi-permanent or permanent filler in the intended injection area. * Presenting with a cutaneous disorder, inflammation or infection near to the treatment area. * Known hypersensitivity to lidocaine and/or lidocaine HCl or hyaluronic acid. * Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder. * Undergoing or planning to undergo peeling treatment or laser-/ultrasound-based treatment within 3 weeks before or after injection. * Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed. * Subject who has a condition or is in a situation that, in the investigator's opinion, may put the subject at significant risk, or may significantly interfere with the subject's participation in the study or with protocol evaluation parameters.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild defects of the lips are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild defects of the lips

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Glyance Ltd

    RECRUITING

    Lod, Israel, 7152026, Israel